Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients

Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Academy of Dermatology 2021-12, Vol.85 (6), p.e371-e372
Hauptverfasser: Siscos, Spyros M., Neill, Brett C., Tarantino, Isadore S., Aires, Daniel J., Rajpara, Anand
Format: Artikel
Sprache:eng
Schlagworte:
Anti-Infective Agents - therapeutic use
Dapsone - therapeutic use
Drug Therapy, Combination
Humans
Pneumonia, Pneumocystis - prevention & control
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e372
container_issue 6
container_start_page e371
container_title Journal of the American Academy of Dermatology
container_volume 85
creator Siscos, Spyros M.
Neill, Brett C.
Tarantino, Isadore S.
Aires, Daniel J.
Rajpara, Anand
description
doi_str_mv 10.1016/j.jaad.2019.04.039
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2213924508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962219306322</els_id><sourcerecordid>2213924508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-41049555f98752ebe0fd0b039d6bdb7c99133ffddecba812822a71c2a89a70ef3</originalsourceid><addsrcrecordid>eNp9UMFu1DAUtBCIbgs_wAH5yCXh2UnWMeKCWgpIlUAIzpZjv1CvEjvYzqrLiU_H2y0cOT2992ZGM0PICwY1A7Z9vat3WtuaA5M1tDU08hHZMJCi2opePCab8oBKbjk_I-cp7QBAto14Ss6awu-AwYb8_oppCT7hG3qllxQ8Um332mf9AxMNe4w0Rzdjvg1LmVVap1Hfr3f6V5iQjiHSLx7XOZhDyi7R5X7xTtMlhuX2MOm7cnWeunlefRjWaQprgens0Of0jDwZ9ZTw-cO8IN-v33-7_FjdfP7w6fLdTWUaELlqGbSy67pR9qLjOCCMFoYS2W4HOwgjJWuacbQWzaB7xnvOtWCG615qATg2F-TVSbe4-rliymp2yeA0aY_Fj-KcNZK3HfQFyk9QE0NKEUd1jK7jQTFQx-bVTh2bV8fmFbSq2Ciklw_66zCj_Uf5W3UBvD0BsKTcO4wqmdKAQesimqxscP_T_wMSkZlX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2213924508</pqid></control><display><type>article</type><title>Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Siscos, Spyros M. ; Neill, Brett C. ; Tarantino, Isadore S. ; Aires, Daniel J. ; Rajpara, Anand</creator><creatorcontrib>Siscos, Spyros M. ; Neill, Brett C. ; Tarantino, Isadore S. ; Aires, Daniel J. ; Rajpara, Anand</creatorcontrib><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2019.04.039</identifier><identifier>PMID: 31015010</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anti-Infective Agents - therapeutic use ; Dapsone - therapeutic use ; Drug Therapy, Combination ; Humans ; Pneumonia, Pneumocystis - prevention &amp; control ; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><ispartof>Journal of the American Academy of Dermatology, 2021-12, Vol.85 (6), p.e371-e372</ispartof><rights>2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-41049555f98752ebe0fd0b039d6bdb7c99133ffddecba812822a71c2a89a70ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962219306322$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31015010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Siscos, Spyros M.</creatorcontrib><creatorcontrib>Neill, Brett C.</creatorcontrib><creatorcontrib>Tarantino, Isadore S.</creatorcontrib><creatorcontrib>Aires, Daniel J.</creatorcontrib><creatorcontrib>Rajpara, Anand</creatorcontrib><title>Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><subject>Anti-Infective Agents - therapeutic use</subject><subject>Dapsone - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Pneumonia, Pneumocystis - prevention &amp; control</subject><subject>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UMFu1DAUtBCIbgs_wAH5yCXh2UnWMeKCWgpIlUAIzpZjv1CvEjvYzqrLiU_H2y0cOT2992ZGM0PICwY1A7Z9vat3WtuaA5M1tDU08hHZMJCi2opePCab8oBKbjk_I-cp7QBAto14Ss6awu-AwYb8_oppCT7hG3qllxQ8Um332mf9AxMNe4w0Rzdjvg1LmVVap1Hfr3f6V5iQjiHSLx7XOZhDyi7R5X7xTtMlhuX2MOm7cnWeunlefRjWaQprgens0Of0jDwZ9ZTw-cO8IN-v33-7_FjdfP7w6fLdTWUaELlqGbSy67pR9qLjOCCMFoYS2W4HOwgjJWuacbQWzaB7xnvOtWCG615qATg2F-TVSbe4-rliymp2yeA0aY_Fj-KcNZK3HfQFyk9QE0NKEUd1jK7jQTFQx-bVTh2bV8fmFbSq2Ciklw_66zCj_Uf5W3UBvD0BsKTcO4wqmdKAQesimqxscP_T_wMSkZlX</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Siscos, Spyros M.</creator><creator>Neill, Brett C.</creator><creator>Tarantino, Isadore S.</creator><creator>Aires, Daniel J.</creator><creator>Rajpara, Anand</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients</title><author>Siscos, Spyros M. ; Neill, Brett C. ; Tarantino, Isadore S. ; Aires, Daniel J. ; Rajpara, Anand</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-41049555f98752ebe0fd0b039d6bdb7c99133ffddecba812822a71c2a89a70ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Infective Agents - therapeutic use</topic><topic>Dapsone - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Pneumonia, Pneumocystis - prevention &amp; control</topic><topic>Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Siscos, Spyros M.</creatorcontrib><creatorcontrib>Neill, Brett C.</creatorcontrib><creatorcontrib>Tarantino, Isadore S.</creatorcontrib><creatorcontrib>Aires, Daniel J.</creatorcontrib><creatorcontrib>Rajpara, Anand</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Siscos, Spyros M.</au><au>Neill, Brett C.</au><au>Tarantino, Isadore S.</au><au>Aires, Daniel J.</au><au>Rajpara, Anand</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>85</volume><issue>6</issue><spage>e371</spage><epage>e372</epage><pages>e371-e372</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31015010</pmid><doi>10.1016/j.jaad.2019.04.039</doi></addata></record>
fulltext fulltext
identifier ISSN: 0190-9622
ispartof Journal of the American Academy of Dermatology, 2021-12, Vol.85 (6), p.e371-e372
issn 0190-9622
1097-6787
language eng
recordid cdi_proquest_miscellaneous_2213924508
source MEDLINE; Elsevier ScienceDirect Journals
subjects Anti-Infective Agents - therapeutic use
Dapsone - therapeutic use
Drug Therapy, Combination
Humans
Pneumonia, Pneumocystis - prevention & control
Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use
title Response: Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T05%3A44%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response:%20Dapsone%20advantages%20over%20trimethoprim-sulfamethoxazole%20for%20Pneumocystis%20pneumonia%20prophylaxis%20in%20immunobullous%20patients&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Siscos,%20Spyros%20M.&rft.date=2021-12&rft.volume=85&rft.issue=6&rft.spage=e371&rft.epage=e372&rft.pages=e371-e372&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2019.04.039&rft_dat=%3Cproquest_cross%3E2213924508%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2213924508&rft_id=info:pmid/31015010&rft_els_id=S0190962219306322&rfr_iscdi=true